CLLS Cellectis S.A.

18.02
-0.22  -1%
Previous Close 18.24
Open 18.5
Price To Book 2.24
Market Cap 764,870,955
Shares 42,445,669
Volume 408,200
Short Ratio
Av. Daily Volume 136,301
Stock charts supplied by TradingView

NewsSee all news

  1. First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

    AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process & New IND Number First Patient Dosed at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS)

  2. Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

    SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis

  3. Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

    Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology

  4. 1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

    BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies

  5. Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

    European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System Regulatory News: Cellectis ((Euronext

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated in 2020.
UCART19 (PALL)
Acute lymphoblastic leukemia (ALL)
Phase 1 initiation of dosing in dose expansion trial announced January 15, 2020.
UCART123 - AMELI-01
Acute myeloid leukemia (AML)
Phase 1 trial ongoing.
UCART19 - CALM
Refractory B-cell Acute Lymphoblastic Leukaemia
Phase 1 trial initiation announced October 29, 2019.
UCARTCS1A
Multiple Myeloma
Phase 1 commencement of enrolment announced December 2, 2019.
UCART22
Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)

Latest News

  1. First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

    AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process & New IND Number First Patient Dosed at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS)

  2. Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

    SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis

  3. Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

    Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology

  4. 1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

    BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies

  5. Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

    European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System Regulatory News: Cellectis ((Euronext

  6. Cellectis Publishes Creation of "Smart CAR T-Cells" for Potentially Safer, More Effective Treatments for Cancer in Nature Communications

    Cellectis Researchers Build CAR T-Cells Able to Sense and React to Their Environment by Secreting Therapeutic Proteins That Improve Their Ability to Fight Cancerous Cells Regulatory News: Cellectis (Paris:ALCLS)

  7. Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

    First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with UCART22 in BALLI-01 Phase 1 dose-escalation clinical trial

  8. Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST

    Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR

  9. First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma

    Cellectis' UCARTCS1 MELANI-01 Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) ((Euronext Growth: ALCLS, NASDAQ:CLLS), a biopharmaceutical company focused on

  10. Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates

    Agreement covers manufacturing of clinical supply for Cellectis' UCART pipeline Manufacturing to take place at Lonza's GMP site in Geleen, Netherlands Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS)